Hyperthermia combined with immune checkpoint inhibitor therapy: Synergistic sensitization and clinical outcomes
Abstract Background Within the field of oncotherapy, research interest regarding immunotherapy has risen to the point that it is now seen as a key application. However, inherent disadvantages of immune checkpoint inhibitors (ICIs), such as their low response rates and immune‐related adverse events (...
| Päätekijät: | , , , , , |
|---|---|
| Aineistotyyppi: | Artikkeli |
| Kieli: | English |
| Julkaistu: |
Wiley
2023-02-01
|
| Sarja: | Cancer Medicine |
| Aiheet: | |
| Linkit: | https://doi.org/10.1002/cam4.5085 |